Methods and kits for preventing hypoglycemia
Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
1. A method for treating an insulin-dependent human patient, comprising the steps of:
a. administering insulin to said patient, wherein said patient has neuropathy;
b. administering subcutaneously to said patient a therapeutic dose of pegylated C-peptide in a different site as that used for said patient's insulin administration; and
c. adjusting the dosage amount, type, or frequency of insulin administered based on monitoring said patient's altered insulin requirements resulting from said therapeutic dose of pegylated C-peptide, wherein said adjusted dose of insulin reduces the risk, incidence, or severity of hypoglycemia, wherein said adjusted dose of insulin is at least 10% less than said patient's insulin dose prior to starting pegylated C-peptide treatment.
2. The method of claim 1 , wherein said patient has established neuropathy.
3. The method of claim 1 , wherein said patient is being treated for a long-term complication of type 1 diabetes.
4. The method of claim 1 , wherein the hypoglycemia is severe hypoglycemia.
5. The method of claim 1 , wherein the hypoglycemia is asymptomatic hypoglycemia.
6. The method of claim 1 wherein said therapeutic dose of pegylated C-peptide is from about 1.5 mg to about 4.5 mg/24 hours.
7. The method of claim 1 , wherein said administration of pegylated C-peptide is via a sustained release composition or device.
8. The method of claim 1 , wherein said adjusted dose of insulin is at about 10% to about 35% less than said patient's insulin dose prior to starting pegylated C-peptide treatment.
9. The method of claim 1 , wherein said therapeutic dose of pegylated C-peptide has been administered to said patient for at least one week prior to step c of claim 1 .
10. The method of claim 1 , wherein said patient has type 1.5 diabetes.
11. The method of claim 1 , wherein said therapeutic dose of pegylated C-peptide maintains an average steady state concentration of C-peptide (C ss-ave ) in said patient's plasma of between about 0.2 nM and about 6 nM.
12. A method of reducing insulin usage in an insulin-dependent human patient, comprising the steps of;:
a. administering insulin to said patient, wherein said patient has neuropathy;
b. administering subcutaneously to said patient a therapeutic dose of pegylated C-peptide in a different site as that used for said patient's insulin administration; and
c. adjusting the dosage amount, type, or frequency of insulin administered based on monitoring said patient's altered insulin requirements resulting from said therapeutic dose of pegylated C-peptide, wherein said adjusted dose of insulin does not induce hypoglycemia, wherein said adjusted dose of insulin is at least 10% less than said patient's insulin dose prior to starting pegylated C-peptide treatment.
13. The method of claim 12 , wherein said patient has established neuropathy.
14. The method of claim 12 , wherein said patient is being treated for a long-term complication of type 1 diabetes.
15. The method of claim 12 , wherein said therapeutic dose of pegylated C-peptide is from about 1.5 mg to about 4.5 mg/24 hours.
16. The method of claim 12 , wherein said therapeutic dose of pegylated C-peptide has been administered to said patient for at least one week prior to step c of claim 12 .
17. The method of claim 12 , wherein said adjusted dose of insulin is about 10% to about 35% less than said patient's insulin dose prior to starting pegylated C-peptide treatment.
18. The method of claim 12 , wherein said patient has type 1.5 diabetes.
19. The method of claim 12 , wherein said therapeutic dose of pegylated C-peptide maintains an average steady state concentration of C-peptide (C ss-ave ) in said patient's plasma of between about 0.2 nM and about 6 nM.
20. The method of claim 12 , wherein said monitoring is conducted over an evaluation period of about two weeks after starting pegylated C-peptide therapy.
21. The method of claim 1 wherein said pegylated C-peptide is pegylated human C-peptide.
22. The method of claim 21 wherein said pegylated human C-peptide is a pegylated derivative of Seq. ID No. 1.
23. The method of claim 12 wherein said pegylated C-peptide is pegylated human C-peptide.
24. The method of claim 23 wherein said pegylated human C-peptide is a pegylated derivative of Seq. ID No. 1.